These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17409892)

  • 21. Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.
    Hsu JS; Huang MS; Chen CY; Liu GC; Liu TC; Chong IW; Chou SH; Yang CJ
    J Thorac Imaging; 2014 Nov; 29(6):357-63. PubMed ID: 25303964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
    Suh YJ; Lee HJ; Kim YJ; Kim KG; Kim H; Jeon YK; Kim YT
    Lung Cancer; 2018 Sep; 123():52-59. PubMed ID: 30089595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
    Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
    Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.
    Ohtsuka K; Ohnishi H; Furuyashiki G; Nogami H; Koshiishi Y; Ooide A; Matsushima S; Watanabe T; Goya T
    J Thorac Oncol; 2006 Oct; 1(8):787-95. PubMed ID: 17409961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of CT-guided fine needle aspiration biopsy in epidermal growth factor receptor mutation analysis in patients with advanced lung cancer.
    Zhuang YP; Wang HY; Shi MQ; Zhang J; Feng Y
    Acta Radiol; 2011 Dec; 52(10):1083-7. PubMed ID: 22006985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation exploration among CT imaging, pathology and genotype of pulmonary ground-glass opacity.
    Cai Y; Chen T; Zhang S; Tan M; Wang J
    J Cell Mol Med; 2023 Jul; 27(14):2021-2031. PubMed ID: 37340599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
    Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
    Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
    Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
    Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
    Wu YL; Zhong WZ; Li LY; Zhang XT; Zhang L; Zhou CC; Liu W; Jiang B; Mu XL; Lin JY; Zhou Q; Xu CR; Wang Z; Zhang GC; Mok T
    J Thorac Oncol; 2007 May; 2(5):430-9. PubMed ID: 17473659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology.
    Park EA; Lee HJ; Kim YT; Kang CH; Kang KW; Jeon YK; Goo JM; Lee CH; Park CM
    Lung Cancer; 2009 May; 64(2):179-86. PubMed ID: 18819724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.